A Phase I/II, Randomized, Double-blind, Placebo, and Active Controlled Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, and Preliminary Efficacy of JHM03 in Subjects With Moderate to Severe Glabellar Lines

Inclusion Criteria: 1. Male or female subjects between 18 and 65 years of age. 2. Moderate to severe glabellar lines at maximum frown at baseline. Exclusion Criteria: 1. Previous use of any botulinum toxin within 6 months prior to screening, or plan to use any botulinum toxin during the study. 2. Use of medications that affect neuromuscular transmission within 4 weeks prior to screening, such as muscle relaxant,aminoglycoside antibiotics,anticholinergic drugs,benzodiazepines,etc. 3. Suffering from any neurological disorders that increase the risk of exposure to botulinum toxin type A, including peripheral motor nerve diseases (such as amyotrophic lateral sclerosis and motor neuropathy), as well as neuromuscular junction diseases (such as Lambert-Eaton syndrome and myasthenia gravis). 4. Known allergy or hypersensitivity to any component of the study products. 5. Use of any non-steroid anti-inflammatory drug or anticoagulant within 1 week prior to study treatment. 6. History of alcohol or drug abuse.